603363.SHG Fujian Aonong Biological Technology Group Incorporation Ltd
- Market cap
- CNY 7.32B
- P/E
- -
- P/B
- 2.61x
- ROE
- -18.9%
- Dividend yield
- 1.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603363.SHG undervalued?
Graham numberThe Graham number of Fujian Aonong Biological Technology Group Incorporation Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fujian Aonong Biological Technology Group Incorporation Ltd fundamental analysis
No fundamental analysis for Fujian Aonong Biological Technology Group Incorporation Ltd yet.
Fujian Aonong Biological Technology Group Incorporation Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fujian Aonong Biological Technology Group Incorporation Ltd
Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig farming, food, supply chain services, and other businesses in China and internationally. It researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant, and other products; and operates pig breeding farms. The company also engages in the pig slaughtering and processing activities, as well as raw materials trade. In addition, it offer…
Full company profileFujian Aonong Biological Technology Group Incorporation Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fujian Aonong Biological Technology Group Incorporation Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.98B | 4.90B | 5.76B | 5.79B | 11.5B | 18.0B | 21.6B | 19.5B | 8.76B | 8.47B | 9.36B |
| Gross Profit | 871M | 924M | 782M | 737M | 1.99B | -170M | 657M | -1.31B | 396M | 533M | 124M |
| Operating Income | 113M | 149M | 21.6M | 78.1M | 966M | -1.81B | -1.31B | -3.65B | 417M | -40.0M | -516M |
| EBITDA | 193M | 251M | 195M | 333M | 1.49B | -575M | 233M | -1.78B | -249M | 722M | -537M |
| Net Income | 91.4M | 108M | 30.1M | 29.2M | 573M | -1.52B | -1.04B | -3.65B | 579M | 77.6M | -522M |
| EPS | 0.19 | 0.22 | 0.05 | 0.05 | 0.91 | -2.76 | -1.34 | -4.21 | 0.67 | 0.03 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 1.71B | 2.54B | 3.31B | 4.92B | 12.0B | 17.1B | 18.7B | 13.6B | 9.51B | 8.74B | 8.84B |
| Total Liabilities | 1.12B | 1.57B | 2.30B | 3.64B | 8.12B | 14.9B | 15.2B | 14.1B | 6.44B | 5.16B | 5.75B |
| Shareholders' Equity | 473M | 808M | 814M | 828M | 2.74B | 1.30B | 2.50B | -963M | 2.57B | 3.13B | 2.76B |
| Cash & Short-term Investments | 174M | 229M | 171M | 255M | 572M | 544M | 722M | 212M | 1.39B | 698M | 487M |
| Total Debt | 385M | 751M | 1.24B | 1.54B | 4.50B | 9.21B | 8.98B | 6.18B | 2.40B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 129M | 26.8M | 27.3M | 394M | 406M | 524M | 664M | 984M | -117M | 153M | - |
| Capital Expenditure | 276M | 440M | 569M | 658M | 3.29B | 2.71B | 1.50B | 512M | 263M | 230M | 117M |
| Free Cash Flow | -147M | -413M | -542M | -264M | -2.89B | -2.18B | -835M | 472M | -379M | -77.0M | -589M |
| Ratios | |||||||||||
| ROE | 19.3% | 13.4% | 3.7% | 3.5% | 20.9% | -116.6% | -41.5% | - | 22.6% | 2.5% | -18.9% |
| ROA | 5.3% | 4.3% | 0.9% | 0.6% | 4.8% | -8.9% | -5.6% | -26.8% | 6.1% | 0.9% | -5.9% |
| Net Profit Margin | 1.8% | 2.2% | 0.5% | 0.5% | 5.0% | -8.4% | -4.8% | -18.8% | 6.6% | 0.9% | -5.6% |
| Debt to Equity | 0.81x | 0.93x | 1.52x | 1.85x | 1.64x | 7.07x | 3.59x | - | 0.94x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fujian Aonong Biological Technology Group Incorporation Ltd dividends
- Dividend yield
- 1.15%
- Forward dividend
- -
- Payout ratio
- 108.9%
- Ex-dividend date
- Jun 8, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 84.5M | 0.03 | 108.9% |
| 2024 | CNY 76.4M | 0.09 | 13.2% |
| 2023 | CNY 295M | 0.34 | - |
| 2022 | CNY 374M | 0.48 | - |
| 2021 | CNY 103M | 0.19 | - |
| 2020 | CNY 51.8M | 0.08 | 9.0% |
| 2019 | CNY 10.9M | 0.02 | 37.2% |
| 2018 | CNY 73.7M | 0.13 | 244.6% |
| 2017 | CNY 26.1M | 0.05 | 24.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Oct 21, 2020.
Who owns Fujian Aonong Biological Technology Group Incorporation Ltd
- Insiders 35.27%
- Institutions 4.16%
- Public & others 60.57%
- Shares outstanding 2.73B
- Free float 1.97B
Fujian Aonong Biological Technology Group Incorporation Ltd company profile
- Company name
- Fujian Aonong Biological Technology Group Incorporation Ltd
- Ticker
- 603363.SHG
- ISIN
- CNE100002VK6
- Exchange
- Shanghai Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 5,126
- Fiscal year end
- December
- Address
- The intersection of Xingting Road and Baolian Road, Zhangzhou, China, 363000
- Phone
- 86 59 2536 2996
- Website
- aonong.com.cn
About Fujian Aonong Biological Technology Group Incorporation Ltd
Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig farming, food, supply chain services, and other businesses in China and internationally. It researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant, and other products; and operates pig breeding farms. The company also engages in the pig slaughtering and processing activities, as well as raw materials trade. In addition, it offers feed, live pigs, pork, and meat products. Fujian Aonong Biological Technology Group Incorporation Limited was founded in 2011 and is based in Zhangzhou, China.
Fujian Aonong Biological Technology Group Incorporation Ltd management
6- Mr. You Lin WuVice Chairman & GM · born 1978
- Mr. Zhou YangVice General Manager & CFO · born 1981
- Mr. Qiang LinDeputy GM, VP of Food Industry & President of Xiamen Yinxiang Meat · born 1970
- Mr. Jiang PengDeputy GM & Secretary of the Board · born 1983
- Mr. Shao Yong HuDeputy General Manager · born 1972
- Jianping YangAccounting Supervisor